Search the Newsreel

Artelo Plans Q4 Trial After ART26.12 Matches Naproxen for Pain

Artelo Biosciences reported its Q2 2026 financial results, with a narrowed net loss of $2.4 million and positive pipeline updates. The company plans a Phase 1 multiple ascending dose study for ART26.12 in Q4 2026, which has shown pain relief comparable to naproxen in …

Artelo Biosciences (ARTL) investors disclose 4.8% stake via Intracoastal warrant

Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC have disclosed a 4.8% beneficial ownership stake in Artelo Biosciences (ARTL) through a warrant held by Intracoastal. This ownership amounts to 173,914 shares of common stock, issuable upon the warrant's exercise, and is based …

Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results

Artelo Biosciences Clinical and Scientific Progress Across the Pipeline Supports Multiple Upcoming Milestones SOLANA BEACH, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for …

Heartland Express, Inc. (HTLD) Stock Forecasts

Argus has lowered its target price for Heartland Express Inc. (HTLD) to $12.00, citing the company's engagement in truckload services across North America. The current stock price for HTLD is $12.68. The report recommends upgrading for premium research and detailed company insights.

Heartland Express Inc (HTLD) Shares Surge 4.2% -- What GF Score of 66 Tells Investors

Heartland Express Inc (HTLD) shares surged 4.2% despite a 17.0% decline over the past month, yet GuruFocus assesses the stock as significantly overvalued with a GF Value of $7.89 against a current price of $12.29. The company's GF Score of 66/100, driven by strong …

Artelo Biosciences (ARTL) trims liabilities, boosts cash amid $5.4M H1 loss

Artelo Biosciences reported a net loss of $5.4 million for the first half of 2026 but significantly improved its liquidity and balance sheet. The company increased cash and cash equivalents to $4.2 million from $0.6 million at year-end 2025 and reduced total liabilities from …

Is Heartland Express (HTLD) Stock Outpacing Its Transportation Peers This Year?

Artelo Biosciences Enrolls First Patient In Phase 2 Glaucoma Study Of ART27.13

(RTTNews) - Artelo Biosciences, Inc. (ARTL), a clinical-stage pharmaceutical company focused on lipid-signaling pathways, announced the enrollment of the first patient in the Phase 2 DREAM study evaluating ART27.13 in patients with glaucoma or ocular hypertension. The investigator-led DREAM study is designed to evaluate …

Heartland Express returns to profit in Q2 FY26; revenue falls 12.5% to 184.13 million

Heartland Express reported a return to profit in Q2 FY26 with a net income of $10.6 million, reversing a net loss from the previous year. Despite a 12.5% decline in revenue to $184.1 million due to strategic fleet changes, the operating ratio improved to …

Artelo Enrolls First Patient In Phase 2 DREAM Trial For ART27.13 In Treating Intralocular Pressure

(RTTNews) - Artelo Biosciences Inc. (ARTL), a clinical-stage pharmaceutical company, on Monday announced the enrollment of the first patient in the Phase 2 DREAM trial for ART27.13 in treating glaucoma or ocular hypertension. Glaucoma affects about 80 million people worldwide and often leads to …

Heartland Express Inc Q2 2026: Revenue $184.1M, EPS $0.14— 10-Q Summary

Heartland Express Inc. (HTLD) reported its Q2 2026 results, showing revenue of $184.1 million and diluted EPS of $0.14. This marks a significant turnaround from a net loss in the prior-year quarter, primarily due to improved freight pricing amid tightened industry capacity. The company …

Artelo Tests an Oral Cannabinoid for Glaucoma Eye Pressure

Artelo Biosciences has dosed the first patient in its Phase 2 DREAM study, evaluating the oral synthetic cannabinoid ART27.13 for glaucoma and ocular hypertension. The study, funded by Glaucoma UK and HSC R&D Division and led by Professor Augusto Azuara-Blanco, aims to assess ART27.13's …

Price to sales forward of Artelo Biosciences, Inc. – NASDAQ:ARTL

This article displays the "Price to sales forward" metric for Artelo Biosciences, Inc. (NASDAQ: ARTL) on the TradingView platform. It provides financial data for the company, noting the market is currently closed with no trades. The primary content is a financial data point for …

Enterprise value to revenue forward of Artelo Biosciences, Inc. – NASDAQ:ARTL

Responsive Playbooks and the HTLD Inflection

Stock Traders Daily's AI models have generated responsive playbooks for Heartland Express Inc. (NASDAQ: HTLD), revealing divergent sentiment across all time horizons and elevated downside risk. The analysis includes institutional trading strategies with specific entry, target, and stop-loss zones for long, breakout, and short …

Smartlink Net Consolidated June 2026 Net Sales at Rs 65.27 crore, up 76.31% Y-o-Y

Heartland Express Inc (HTLD) Earnings Forecast: Future EPS & Revenue Growth Estimates

Heartland Express Inc (HTLD) has an earnings forecast score of 6.00, ranking 53 out of 76 in its industry, with an average price target of $8.00. Six analysts currently rate the stock as "Hold." The company's expected revenue for the next quarter is $192.44 …

Heartland Express, Inc. (NASDAQ:HTLD) Given Consensus Recommendation of "Hold" by Analysts

Analysts have issued a consensus "Hold" rating for Heartland Express, Inc. (NASDAQ:HTLD), with an average 12-month price target of $13.20. The company recently reported quarterly EPS of $0.14, falling short of expectations, and experienced a 12.5% year-over-year decline in revenue. A director sold over …

Tranche Update on Heartland Express, Inc.'s Equity Buyback Plan announced on August 20, 2021.

Heartland Express, Inc. announced an update on its equity buyback plan from August 20, 2021. Between April 1, 2026, and June 30, 2026, the company repurchased no shares for $0 million. This means the company has completed repurchases of 0 shares for $0 million …

Heartland Express reports Q2 2026 net income $10.6M, operating revenue $184.1M; operating ratio 91.0%

Heartland Express reported Q2 2026 net income of $10.6 million on operating revenue of $184.1 million, achieving an operating ratio of 91.0%. The company highlighted continued operating-ratio improvement, significant debt reduction, and planned reinvestment in its fleet for the remainder of 2026. Financial metrics …

Heartland Express Reports $10.6 Million Q2 Net Income as Revenue Falls

Heartland Express (HTLD) reported a net income of $10.6 million for Q2 2026, a significant improvement from a net loss in the same period last year, despite a decrease in operating revenue to $184.1 million. The company's basic earnings per share reached $0.14, and …

Smartlink Holdings Limited Announces Retirement of Pradeep Anant Rane as Independent Director, Effective August 04, 2026

Heartland Express (HTLD) Earnings Date and Reports 2026 $HTLD

Heartland Express: Q2 Earnings Snapshot

This article provides a brief snapshot of Heartland Express's Q2 earnings. No specific financial details are provided beyond the headline.

Dimensional Fund Advisors LP Increases Position in Heartland Express, Inc. $HTLD

Heartland Express Bounces Back to Profitability in Second Quarter 2026

Heartland Express reported a return to profitability in Q2 2026, achieving a net income of $10.6 million compared to a net loss in the prior year. This turnaround was driven by operational cost cuts, improved customer pricing, and strategic asset disposals, despite a decrease …

Smartlink Networks Q1 FY27 Results: PAT Rs 5 Cr, Revenue Rs 65 Cr

Arrowstreet Capital Limited Partnership Has $6.12 Million Holdings in Heartland Express, Inc. $HTLD

Artelo Biosciences Market Sentiment

This article analyzes market sentiment for Artelo Biosciences (ARTL) based on analyst consensus, short interest, options flow, and insider activity. It highlights a "Buy" consensus from four analysts with an average price target of $6, and notes a 4.8% declining short float. The report …

Wall Street Zen Upgrades Heartland Express (NASDAQ:HTLD) to Buy

Smartlink Holdings consolidated net profit rises 157.34% in the June 2026 quarter

Heartland Express (HTLD) Stock Rebounds To Profit As Revenue Shrinks

HTLD Maintained by JP Morgan -- Price Target Raised to $12.00

JP Morgan has maintained an "Underweight" rating on Heartland Express (HTLD) but raised its price target from $11.00 to $12.00. GuruFocus assesses HTLD as significantly overvalued with a GF Value™ of $7.98 against its current price of $12.46, and notes a moderate GF Score™ …